Market Place
Sourcing Support
All News #Library
Others
Reven’s anti-sepsis drug provides rapid recovery in Covid-19 trial
27 Sep 2021 //
CLINICALTRIALSARENA
Reven’s Co-Founder Michael Volk Appears on Cheddar News
09 Jul 2021 //
BUSINESSWIRE
Reven Reports a Promising Second Generation Formulation of Rejuveinix
18 Jun 2021 //
BUSINESSWIRE
Reven Pharma Reports a Promising 2nd Generation Formulation of Rejuveinix (RJX)
18 Jun 2021 //
BUSINESSWIRE
Reven Reports Positive Results Regarding the Safety and Preclinical Efficacy
11 Nov 2020 //
BIOSPACE
Reven Wins FDA Approval of Its IND Application for Rejuveinix (RJX)
23 Oct 2020 //
BIOSPACE
Reven Strengthens Its Clinical Team With Three New Members
05 Oct 2020 //
BUSINESSWIRE
Reven Selects eClinical Services Provider DSG Clinical Data Management Services
30 Sep 2020 //
BUSINESSWIRE
Reven Selects eClinical Services Provider DSG Clinical Data Management Services
29 Sep 2020 //
BUSINESSWIRE
Reven’s Patent Application to Issue as a New Patent
16 Sep 2020 //
BUSINESSWIRE
Reven Patented, First-in-Class Anti-inflammatory Treatment for Sepsis on Track
14 Sep 2020 //
BIOSPACE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.